**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 12205**

**Columns:** **RETROSPECTIVE STUDY**

**Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients**

Kim DH *et al.* Preoperative CA 125 in gastric cancer

Dae Hoon Kim, HyoYung Yun, Dong Hee Ryu, Hye-Suk Han,Joung-Ho Han, Soon Man Yoon, Sei Jin Youn

**Dae Hoon Kim, HyoYung Yun, Dong Hee Ryu,** Department of Surgery, Chungbuk National University College of Medicine, Cheongju 361-763, South Korea

**Hye-Suk Han,Joung-Ho Han, Soon Man Yoon, Sei Jin Youn,** Internal Medicine, Chungbuk National University College of Medicine, Cheongju 361-763, South Korea

**Author contributions:** Yun H designed the study; Kim DH and Yun H wrote the manuscript; Kim DH and Ryu DH provided the collection of data; Han H, Han J, Yoon SM and YounSJ involved in editing the manuscript.

**Supported by** Research grant of Chungbuk National University in 2013

**Correspondence to: HyoYung Yun, MD, PhD,** Department of Surgery, Chungbuk National University College of Medicine**,** 410 Sungbong-ro, Heungduk-gu, Cheongju 361-763, South Korea. unhyo@chungbuk.ac.kr

**Telephone**: +82-43-2696032 **Fax**: +82-43-2666037

**Received:** June 27, 2014 **Revised:** August 20, 2014

**Accepted:** September 29, 2014

**Published online:**

**Abstract**

**AIM:** To investigate the correlation among tumor markers, curative resection, and recurrence in gastric cancer.

**METHODS:** The patients with preoperative tumor makers (Carcinoembryonic antigen, CA 19-9, and CA 125) and elective gastrectomy between January 2000 and December 2009 at Chungbuk National University Hospital were enrolled in this study. We analyzed the relationship among the tumor makers, curative resection and recurrence, retrospectively.

**RESULTS:** Among the 679 patients with gastric cancer, curative resection was 93.6% (*n* = 636) and non–curative resection was 6.4% (*n* = 43). The independent risk factors for the non-curative resection were tumor location and the positivity of preoperative serum CA 19-9 and CA 125 levels. After curative resection, the independent prognostic risk factors for recurrence in curative resection were gender, stage, and preoperative increased serum CA 125 level (HR = 2.431, *P =*0.020), in a multivariate analysis.

**CONCLUSION:** Preoperative CA 125 is a useful predictive biomarker for curative resection and prognostic biomarker for recurrence in gastric cancer patients.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Gastric Cancer; Tumor Marker; CEA; CA 19-9; CA 125

**Core tip:** Tumor marker such as carcinoembryonic antigen, CA 19-9, and CA 125 in gastric cancer are usual tools for predicting prognosis or monitoring. The aim of this study was to investigate the correlation among tumor markers, curative resection, and recurrence in gastric cancer. Our data showed that preoperative CA 19-9 and CA 125 are independent risk factor of non-curative operation. And preoperative CA 125 is independent risk factor for recurrence after curative operation. Preoperative CA 125 is considered useful marker for predicting curative operation and prediction of recurrence after curative resection in gastric cancer patients

Kim DH, Yun H, Ryu DH, Han HS, Han JH, Yoon SM, Youn SJ. Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Serum tumor marker is a simple and convenient study for predicting prognosis or monitoring, and it is widely being used in a gastrointestinal malignancy[1]. Carcinoembryonic antigen (CEA) is a glycoprotein that is often elevated in the serum of patients with variety malignancies such as gastric, pancreatic, colorectal, breast and lung cancer[2]. Carbohydrate antigen 19-9 (CA 19-9)is an incomplete glycolipid antigen of the Lewis blood group, and it can be increased in colorectal, liver, ovarian, bile duct and gastric cancer[3]. CEA and CA 19-9 are known prognostic risk factors in gastric cancer[4,5]. In American Joint Committee on Cancer (AJCC) 7th edition, CEA and CA 19-9 been recognized as prognostic factors, but Cancer antigen 125 (CA 125) is not[6]. CA 125 is a heterogeneous cell membrane glycoprotein and it is related with malignant conditions such as ovarian, uterine, lung, or pancreatic cancers[7]. CEA is related to liver metastasis, peritoneal metastasis, histologic type and CA 19-9 is related to T, N stage, and peritoneal dissemination[8]. CA 125 is related to peritoneal dissemination[9]. Peritoneal dissemination, after curative gastrectomy with extended lymphadectomy, is most common recurrence pattern in the east[10]. As diagnosis of peritoneal dissemination is not high as that of distant metastasis and direct invasion of adjacent organs in preoperative image studies[11], surgeons face to unforeseen non-curative operation. It has been reported that CA 125 is related with peritoneal dissemination in gastric cancer[9], but there were few or no studies concerning the correlation between CA 125 and prognosis.

This study was to clarify prognostic value of preoperative CA 125 for prognostic biomarker, and to investigate the correlation between tumor markers (CEA, CA 19-9 and CA 125) and prediction of curative resection in gastric cancer patients.

**MATERIALS AND METHODS**

A total of 679 gastric cancer patients admitted through the outpatient department of surgery from 2000 to 2009 were enrolled. All enrolled patients checked tumor marker before gastric operation and follow-up performed biannually after gastric operation. Preoperative measurement of CEA, CA19-9, and CA 125 were performed by radioimmunoassay. The normal ranges for CEA, CA 19-9, and CA 125 were: < 5 ng/mL, 25 U/mL, and 37 U/mL, respectively. We excluded remnant gastric cancer, synchronous primary malignancy, or gastric cancer with neo-adjuvant therapy. Recurrence pattern was classified into four categories: loco-regional recurrence, peritoneal dissemination, hematogenous and distant lymph node. We performed gastric cancer operation according to Japanese gastric cancer treatment guidelines[12]. Pathologic staging was conducted after the operation according to the AJCC sixth edition[13]. Non-curative operations were defined as microscopically or macroscopically residual tumor after gastric operation.

We retrospectively analyzed the relationship among a non-curative operation, recurrence and tumor marker. We employed SPSS 20.0 for Windows for statistical analyses (SPSS, Inc., Chicago, IL, United States). The chi-square and Fisher’s exact tests were used to assess clinical and pathological characteristics for univariated analysis and logistic regression test for multivariate analsysis. The disease free survival was analyzed using the Kaplan-Meier method, and significance testing was performed with the log-rank test. The Cox proportional hazards model was used for multivariate analysis. Differences with p values less than 0.05 (*P* < 0.05) were considered statistically significant.

**RESULTS**

Of the 679 patients, 447 patients were male and 232 patients were female with a mean age of 60.7 ± 11.4 years, and the median follow-up period was 32.4 mo. Forty-three patients (6.3%) received non-curative operations. The main causes of a non-curative operations were peritoneal dissemination (*n* = 21) followed by direct invasion (*n* = 16). (Table 1) Risk factors for non-curative operation were tumor location, CEA, CA 19-9, and CA 125 in univariate analysis. In a multivariate analysis, location of tumor (HR = 21.303; *P* < 0.001), CA 19-9 positivity (HR = 5.883; *P* < 0.001), and CA 125 positivity (HR = 15.549; *P* < 0.001) were independent risk factors for a non-curative operation. (Table 2) Recurrences after curative operation were 124 cases among 636 patients, and 64 patients had two or more recurrence site; hematogenous (*n* = 72), peritoneal (*n* = 50), loco-regional (*n* = 46) and distant lymph node metastases (*n* = 41). The 5-year disease-free survival rate after curative operation was 77.9%, and the 5-year disease-free survival rate of CEA, CA 19-9 and CA 125 are 51.3%, 51.7% and 30.8%, respectively (Figure 1). Risk factors of recurrence were tumor location, differentiation, lymphovascular invasion, perineural invasion, stage, and CEA, CA 19-9, and CA 125. In a multivariate analysis, gender, stage, and positivity of CA 125 (HR, 2.431; *P* = 0.020) were independent risk factors for recurrence (Table 3).

**DISCUSSION**

Depth of invasion and lymph node metastasis were most important independent prognostic risk factors in gastric cancer, and currently used TNM stage is useful to predicting survival rate in each stage. However, it was difficult to estimate N stage, to predict survival rate in each stage and to decide treatment of modality in preoperative clinical TNM stage. Many prognostic risk factors of gastric cancer were investigated, and tumor marker is one of the prognostic factors of gastric cancer. CEA and CA 19-9 are the most common tumor markers for predicting prognosis in gastric cancer[14]. The sensitivities of CEA and CA 19-9 in gastric cancer are 16%–58.4% and 34.1%–64.9%[15-17]. Preoperative positivity for CEA and CA 19-9 is associated with a poor prognosis[4,5,18], but there is a few report for preoperative CA 125 in gastric cancer. The preoperative CEA and CA 19-9 were not prognostic factor for palliative gastric surgery, but it was independent prognostic factors in curative surgery[4]. The postoperative CEA positivity in early gastric cancer and postoperative CEA and CA 72-4 positivity in advanced gastric cancer were independent prognostic factors[18]. In our study, the preoperative CEA and CA 19-9 were not independent prognostic risk factors for recurrence as other study[19], interestingly preoperative CA 125 was an independent risk factor for recurrence with a HR of 2.431. In early stage (data was not shown), no recurrence observed in the patients with positivity of CA 125 in stage IA (*n* = 2), but there were two cases of recurrences among 4 patients with positivity of CA 125 in stage IB, one is peritoneal carcinomatosis, and the other is loco-regional recurrence, respectively. We think that this finding may be related with recurrence patterns of gastric cancer. The sensitivity of CA 125 is 6%-31.6%[20,21], and it is related with peritoneal metastasis[22]. In the Japan Clinical Oncology Group (JCOG9501) trial, recurrence patterns were peritoneal recurrence, regional lymph node recurrence, hepatic, and others were: 38.1%, 21.9%, 20.9%, and 19.7%, respectively[23]. In Korean study, recurrent patterns were observed according to time period. Hematogenous recurrence was the most common recurrent pattern in the 1990s, whereas peritoneal recurrence was the most common recurrent pattern in the 2000s. Furthermore, peritoneal dissemination was the most frequent recurrence pattern (32.1%) during the entire period[10]. In our study, peritoneal dissemination and hematogenous metastasis were the main recurrence patterns. The positivity of CA 125 may be reflected recurrent patterns of peritoneal dissemination.

In our study, stage I and II are 61.8%, this is why non-curative operation smaller (6.4%) than other studies (17.9%–35.8%)[24,25]. In general, diagnostic accuracy of preoperative T stage in gastric cancer is 65%-92.1%[26]. and sensitivity and specificity of hematogenous metastasis especially liver are 87.5% and 99.0%[27]. Diagnostic accuracy of preoperative for peritoneal metastasis is 30%-100%[27], but sensitivity is only 28.8%[11]. Diagnostic laparoscopy maybe useful for border line peritoneal dissemination in image study. Kapiev *et al*[28] reported that 29.5% of patients with borderline unresectable gastric cancer were diagnosed as peritoneal metastasis by diagnostic laparoscopy. In our study, the proportion of non-curative resection with peritoneal dissemination is low (3.1%), according to our data, diagnostic laparoscopy is not necessary even in far advanced gastric cancer. Peritoneal metastasis is the main cause of non-curative operation in our study and to avoid unnecessary operation precise diagnosis of peritoneal dissemination is important. In general, tumor markers (CEA, CA 19-9 and CA 125) are related with peritoneal dissemination[8,9,22]. There is a few report of relationship between curative resection and preoperative tumor marker. Pectasides *et al*[16] reported that the sensitivity of CEA and CA 19-9 in inoperable or metastatic disease gastric cancer were 48.6% and 64.9%, retrospectively. As compared to our study, their study did not checked tumor marker preoperative, and there was no data of CA 125. In our study, 24.2% and 42.9% of patients with increased levels of CA 19-9 and CA 125 received a non-curative operation. The HRs of CA 19-9 and CA 125 for non-curative operations were 4.153 and 10.796, each representing statistically significant levels. We think that the positivity of CA 19-9 and CA 125 may reflect peritoneal dissemination. Thus, it would be useful biomarker to avoid unnecessary laparotomy for patients with borderline resectability on preoperative imaging test if they show increased CA 19-9 and CA 125 levels.

In far advanced gastric cancer, the positivity of CA 19-9 and CA 125 showed a higher frequency of receiving non-curative operations, a more careful approach is necessary. Additionally, a more aggressive treatment is required even if a curative operation is performed, as preoperative increased CA 125 is related to possible recurrence.

**COMMENTS**

***Background***

Preoperative image study is a useful diagnostic tool for staging in gastric cancer. But its role in resectability and prognosis in a part of gastric cancer patients is questionable. The aim of this study was to investigate the correlation among tumor markers especially CA 125, curative resection, and recurrence in gastric cancer.

***Research frontiers***

CA 125 is related to peritoneal dissemination, and it has been reported that CA 125 is related with peritoneal dissemination in gastric cancer. However, the clinical significant of CA 125 in gastric cancer is not clarified. The current hot spot is to clarify the role of CA 125 in gastric cancer.

***Innovations and breakthroughs***

Previous studies showed that CA 125 is related with peritoneal carcinomatosis in gastric cancer. But, there were few or no studies concerning the relation between preoperative CA 125 and curative operation or prognosis. In our study, the preoperative CA 125 is related with non-curative operation and poor prognosis.

***Applications***

In far advanced gastric cancer, the positivity of CA 125 showed a higher frequency of receiving non-curative operations, a more careful approach is necessary. Additionally, a more aggressive treatment is required even if a curative operation is performed, as preoperative increases in CA 125 are related to possible recurrence.

***Peer review***

This is a retrospective study that analyzes clinical significance of tumor marker in gastric cancer. The results are interesting and show that the positivity of preoperative CA 125 associated with non-curative operations and poor prognosis. This finding suggest that CA 125 is a useful tumor marker predicting non-curative operation and poor prognosis.

**REFERENCES**

1 **Grem J**. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. *Curr Opin Oncol* 1997; **9**: 380-387 [PMID: 9251889 DOI: 10.1097/00001622-199709040-00012]

2 **Fletcher RH**. Carcinoembryonic antigen. *Ann Intern Med* 1986; **104**: 66-73 [PMID: 3510056 DOI: 10.7326/0003-4819-104-1-66]

3 **Lamerz R**. Role of tumour markers, cytogenetics. *Ann Oncol* 1999; **10** Suppl 4: 145-149 [PMID: 10436809 DOI: 0.1093/annonc/10.suppl\_4.s145]

4 **Reiter W**, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fateh-Moghadam A. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. *Anticancer Res* 1997; **17**: 2903-2906 [PMID: 9329559]

5 **Marrelli D**, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, Pinto E. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. *Oncology* 1999; **57**: 55-62 [PMID: 10394126 DOI: 10.1159/000012001]

6 **American Joint of Commutee on Cancer.** AJCC cancer staging manual 7th edition. Springer; New York 2010: 117-121 [DOI: 10.1007/978-0-387-88441-7]

7 **Cragun JM**. Screening for ovarian cancer. *Cancer Control* 2011; **18**: 16-21 [PMID: 21273976]

8 **Ucar E**, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. *Adv Ther* 2008; **25**: 1075-1084 [PMID: 18821070 DOI: 10.1007/s12325-008-0100-4]

9 **Nakata B**, Hirakawa-YS Chung K, Kato Y, Yamashita Y, Maeda K, Onoda N, Sawada T, Sowa M. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. *Cancer* 1998; **83**: 2488-2492 [PMID: 9874453 DOI: 10.1002/(sici)1097-0142(19981215)83: 12<2488:: aid-cncr12>3.0.co; 2-1]

10 **Kim DH**, Kim SM, Hyun JK, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods. *Ann Surg Oncol* 2013; **20**: 2317-2327 [PMID: 23677605 DOI: 10.1245/s10434-012-2700-0]

11 **Leake PA**, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Law C, Coburn NG. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. *Gastric Cancer* 2012; **15** Suppl 1: S38-S47 [PMID: 21667136 DOI: 10.1007/s10120-011-0047-z]

12 **Japanese Gastric Cancer Association.** Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer* 2011; **14**: 113-123 [PMID: 21573742 DOI: 10.1007/s10120-011-0042-4]

13 **Greene FL,** Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002: 89-99

14 **Hur H**, Song KY, Park CH, Jeon HM. Follow-up strategy after curative resection of gastric cancer: a nationwide survey in Korea. *Ann Surg Oncol* 2010; **17**: 54-64 [PMID: 19777193 DOI: 10.1245/s10434-009-0676-1]

15 **Heptner G**, Domschke S, Domschke W. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies. *Scand J Gastroenterol* 1989; **24**: 745-750 [PMID: 2814339 DOI: 10.3109/00365528909093116]

16 **Pectasides D**, Mylonakis A, Kostopoulou M, Papadopoulou M, Triantafillis D, Varthalitis J, Dimitriades M, Athanassiou A. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. *Am J Clin Oncol* 1997; **20**: 348-353 [PMID: 9256887 DOI: 10.1097/00000421-199708000-00005]

17 **Filella X**, Fuster J, Molina R, Grau JJ, García-Valdecasas JC, Grande L, Estapé J, Ballesta AM. TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer. *Acta Oncol* 1994; **33**: 747-751 [PMID: 7993641 DOI: 10.3109/02841869409083943]

18 **Kim DH**, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. *J Surg Oncol* 2011; **104**: 585-591 [PMID: 21695697 DOI: 10.1002/jso.21919]

19 **Gaspar MJ**, Arribas I, Coca MC, Díez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. *Tumour Biol* 2001; **22**: 318-322 [PMID: 11553862 DOI: 10.1159/000050633]

20 **He CZ**, Zhang KH, Li Q, Liu XH, Hong Y, Lv NH. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. *BMC Gastroenterol* 2013; **13**: 87 [PMID: 23672279 DOI: 10.1186/1471-230x-13-87]

21 **Lai IR**, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. *Hepatogastroenterology* 2002; **49**: 1157-1160 [PMID: 12143226]

22 **Hwang GI**, Yoo CH, Sohn BH, Shin JH, Park YL, Kim HD, Kim YS, Han WK, Pae WK. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. *Cancer Res Treat* 2004; **36**: 178-181 [PMID: 20396541 DOI: 10.4143/crt.2004.36.3.178]

23 **Sasako M**, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008; **359**: 453-462 [PMID: 18669424 DOI: 10.1056/NEJMoa0707035]

24 **Huang KH**, Wu CW, Fang WL, Chen JH, Lo SS, Wang RF, Li AF. Palliative resection in noncurative gastric cancer patients. *World J Surg* 2010; **34**: 1015-1021 [PMID: 20145923 DOI: 10.1007/s00268-010-0467-7]

25 **Wang CS**, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF. Benefits of palliative surgery for far-advanced gastric cancer. *Chang Gung Med J* 2002; **25**: 792-802 [PMID: 12635835]

26 **Kwee RM**, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. *J Clin Oncol* 2007; **25**: 2107-2116 [PMID: 17513817 DOI: 10.1200/jco.2006.09.5224]

27 **D'Elia F**, Zingarelli A, Palli D, Grani M. Hydro-dynamic CT preoperative staging of gastric cancer: correlation with pathological findings. A prospective study of 107 cases. *Eur Radiol* 2000; **10**: 1877-1885 [PMID: 11305564 DOI: 10.1007/s003300000537]

28 **Kapiev A**, Rabin I, Lavy R, Chikman B, Shapira Z, Kais H, Poluksht N, Amsalam Y, Halpern Z, Markon I, Wassermann I, Halevy A. The role of diagnostic laparoscopy in the management of patients with gastric cancer. *Isr Med Assoc J* 2010; **12**: 726-728 [PMID: 21348398]

**P-Reviewer:** Koukourakis GV, Mura B **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Table 1 Causes for a non-curative operations**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Peritoneal dissemination** | **Direct invasion** | **Distant metastasis** | **Incomplete**  **resection** | **Total** |
| Peritoneal dissemination | 15 | 3 | 3 |  | 21 |
| Direct invasion | 3 | 13 |  |  | 16 |
| Distant metastasis | 3 |  | 3 |  | 6 |
| Incomplete resection |  |  |  | 6 | 6 |
| Total | 21 | 16 | 6 | 6 | 49 |

**Table 2 Univariate and multivariate analysis of the risk factors for a non-curative operations *n* (%)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | | **Univariate analysis** | | |  | **Multivariate analysis** | |
| **Curative** | **Non-curative** | ***P*-value** |  | **HR (95%CI)** | ***P*-value** |
| Age, yr | |  |  | 0.189 |  |  | 0.238 |
|  | < 60 | 272 (95.1) | 14 (4.9) |  |  |  |  |
|  | ≥ 60 | 364 (92.6) | 29 (7.4) |  |  | 1.599 (0.733 - 3.487) |  |
| Sex | |  |  | 0.574 |  |  | 0.642 |
|  | male | 417 (93.3) | 30 (6.7) |  |  |  |  |
|  | female | 219 (94.4) | 13 (5.6) |  |  | 0.832 (0.384- 1.803) |  |
| Differentiation | |  |  | 0.080 |  |  | 0.082 |
|  | differentiated | 382 (95.0) | 20 (5.0) |  |  |  |  |
|  | undifferentiated | 254 (91.7) | 23 (8.3) |  |  | 1.937 (0.919 - 4.085) |  |
| Location | |  |  | < 0.001 |  |  | < 0.001 |
|  | lower 1/3 | 359 (93.2) | 26 (6.8) |  |  |  |  |
|  | middle 1/3 | 212 (97.2) | 6 (2.8) |  |  | 0.334 (0.120 - 0.928) | 0.036 |
|  | upper 1/3 | 60 (90.9) | 6 (9.1) |  |  | 1.223 (0.421 -3.555) | 0.711 |
|  | whole | 5 (50.0) | 5 (50.0) |  |  | 21.303 (4.985- 91.036) | < 0.001 |
| CEA | |  |  | 0.038 |  |  |  |
|  | negative | 579 (94.3) | 35 (5.7) |  |  |  | 0.792 |
|  | positive | 57 (87.7) | 8 (12.3) |  |  | 1.142 (0.427-3.056) |  |
| CA 19-9 | |  |  | < 0.001 |  |  | < 0.001 |
|  | negative | 586 (95.6) | 27 (4.4) |  |  |  |  |
|  | positive | 50 (75.8) | 16 (24.2) |  |  | 5.883 (2.569-13.474) |  |
| CA 125 | |  |  | < 0.001 |  |  | < 0.001 |
|  | negative | 616 (95.7) | 28 (4.3) |  |  |  |  |
|  | positive | 20 (57.1) | 15 (42.9) |  |  | 15.549 (6.473- 37.352) |  |

**Table 3 Univariateand multivariate analysis of prognostic risk factors for disease-free survival after curative operations**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables** | | **Univariate analysis** | |  | **Multivariate analysis** | |
| **5-year DFS %** | ***P-*value** |  | **HR (95% CI)** | ***P-* value** |
| Age, years | |  | 0.865 |  |  | 0.282 |
|  | < 60 (*n* =272) | 78.3% |  |  |  |  |
|  | ≥ 60 (*n* = 364) | 80.1% |  |  | 1.250 (0.833 -1.877) |  |
| Sex | |  | 0.194 |  |  | 0.037 |
|  | male (*n* = 417) | 78.3% |  |  |  |  |
|  | female (*n* = 219) | 81.7% |  |  | 0.616 (0.391-0.971) |  |
| Differentiation | |  | 0.020 |  |  | 0.292 |
|  | differentiated (*n* = 382) | 81.6% |  |  |  |  |
|  | undifferentiated (*n* = 254) | 75.6% |  |  | 0.797 ( 0.524 ~ 1.215) |  |
| Location | |  | 0.004 |  |  | 0.454 |
|  | lower 1/3 (*n* = 359) | 76.0% |  |  |  |  |
|  | middle 1/3 (*n* = 212) | 86.8% |  |  | 0.797 (0.489 -1.297) |  |
|  | upper 1/3 (*n* = 60) | 70.8% |  |  | 1.172 (0.643-2.135) |  |
|  | whole (*n* = 5) | 40.0% |  |  | 0.487 (0.138-1.720) |  |
| Lymphovascular invasion | |  | < 0.001 |  |  | 0.709 |
|  | negative (*n* = 513) | 81.8% |  |  |  |  |
|  | positive (*n* = 123) | 69.4% |  |  | 1.085 (0.708-1.662) |  |
| Perineural invasion | |  | < 0.001 |  |  | 0.072 |
|  | negative (*n* = 582) | 81.4% |  |  |  |  |
|  | positive (*n* = 54) | 54.4% |  |  | 1.629 (0.958-2.770) |  |
| Stage | |  | < 0.001 |  |  | < 0.001 |
|  | IA (*n* = 292) | 98.7% |  |  |  |  |
|  | IB (*n* = 102) | 89.4% |  |  | 6.613 (1.703-25.674) | 0.006 |
|  | II (*n* = 75) | 79.8% |  |  | 15.415 (4.297- 55.300) | < 0.001 |
|  | IIIA (*n* = 69) | 49.5% |  |  | 43.857 (12.999-147.966) | < 0.001 |
|  | IIIB (*n* = 39) | 46.2% |  |  | 66.090 (18.643-234.289) | < 0.001 |
|  | IV (*n* = 59) | 32.7% |  |  | 93.720 (27.252-319.103) | < 0.001 |
| CEA | |  | < 0.001 |  |  | 0.073 |
|  | negative (*n* = 579) | 82.1% |  |  | 1.559 (0.959-2.535) |  |
|  | positive (*n* = 57) | 51.3% |  |  |  |  |
| CA 19-9 | |  | < 0.001 |  |  | 0.694 |
|  | negative (*n* = 586) | 81.7% |  |  |  |  |
|  | positive (*n* = 50) | 51.7% |  |  | 0.901 (0.535-1.516) |  |
| CA 125 | |  | < 0.001 |  |  | 0.020 |
|  | negative (*n* = 616) | 80.6% |  |  |  |  |
|  | positive (*n* = 20) | 30.8% |  |  | 2.431 (1.153-5.123) |  |

**Figure 1 Disease free survival curve according to positivity of CEA (A), CA 19-9 (B) and CA 125 (C).**





